Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00006023 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: capecitabine

Sponsor

Swiss Cancer Institute